Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317779 | 0.87 | LMNA (0.48) | LMNAGAAPOLBCNR1DAGLA | |
| SCHEMBL475421 | 0.87 | LMNA (0.48) | LMNAGAAPOLBCNR1DAGLA | |
| SCHEMBL78947 | 0.87 | LMNA (0.48) | LMNAGAAPOLBCNR1DAGLA | |
| Methylene Chloride SCHEMBL28127319 | 0.81 | LMNA (0.47) | LMNAGAAPOLBCNR1DAGLA | |
| Methylene Chloride SCHEMBL28127317 | 0.81 | LMNA (0.47) | LMNAGAAPOLBCNR1DAGLA | |
| SCHEMBL25401240 | 0.79 | GAA (0.48) | LMNAGAAPOLBCNR1DAGLA | |
| SCHEMBL7514998 | 0.79 | GAA (0.48) | LMNAGAAPOLBCNR1DAGLA | |
| SCHEMBL7515001 | 0.79 | GAA (0.48) | LMNAGAAPOLBCNR1DAGLA | |
| SCHEMBL2241494 | 0.79 | LMNA (0.45) | LMNAGAAPOLBCNR1DAGLA | |
| SCHEMBL3769213 | 0.79 | LMNA (0.45) | LMNAGAAPOLBCNR1DAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | GLUL, GLS, GLS2 | LMNA 4370/4885GAA 46/4885POLB 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.